Viking Therapeutics (VKTX) Financials

$27.01 -2.48 (-8.41%)

Closing price 05/6/2025 04:00 PM Eastern

Extended Trading

$27.36 +0.35 (+1.30%)

As of 08:01 AM Eastern

Annual Income Statements for Viking Therapeutics

This table shows Viking Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-23	-15	-21	-22	-26	-79	-55	-69	-86	-110
Consolidated Net Income / (Loss)	-23	-15	-21	-22	-26	-39	-55	-69	-86	-110
Net Income / (Loss) Continuing Operations	-23	-15	-21	-22	-26	-79	-55	-69	-86	-110
Total Pre-Tax Income	-23	-15	-21	-22	-26	-79	-55	-69	-86	-110
Total Operating Income	-12	-14	-19	-26	-33	-43	-56	-70	-101	-151
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	12	14	19	26	33	85	56	70	101	151
Selling, General & Admin Expense	5.03	4.85	5.33	7.12	9.13	11	11	16	37	49
Research & Development Expense	6.97	9.00	14	19	24	32	45	54	64	102
Amortization Expense	-	-	-	-	-	-	0.02	0.06	0.09	0.09
Total Other Income / (Expense), net	-11	-0.88	-1.51	4.10	6.91	6.33	0.71	1.55	15	41
Interest & Investment Income	-0.09	-0.02	0.00	3.24	7.05	3.23	0.70	1.59	15	41
Other Income / (Expense), net	-10	0.93	-0.23	1.27	-0.15	3.10	0.01	-0.04	0.00	0.11
Basic Earnings per Share	($3.68)	($0.90)	($0.79)	($0.38)	($0.36)	($0.54)	($0.71)	($0.90)	($0.91)	($1.01)
Weighted Average Basic Shares Outstanding	6.36M	16.28M	25.98M	57.58M	71.96M	72.60M	77.20M	76.83M	94.35M	109.04M
Diluted Earnings per Share	($3.68)	($0.90)	($0.79)	($0.38)	($0.36)	($0.54)	($0.71)	($0.90)	($0.91)	($1.01)
Weighted Average Diluted Shares Outstanding	6.36M	16.28M	25.98M	57.58M	71.96M	72.60M	77.20M	76.83M	94.35M	109.04M
Weighted Average Basic & Diluted Shares Outstanding	6.36M	16.28M	25.98M	57.58M	71.96M	72.60M	77.20M	78.42M	100.49M	112.25M

This table shows Viking Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-16	-20	-20	-19	-23	-25	-27	-22	-25	-35	-46
Consolidated Net Income / (Loss)	-16	-20	-20	-19	-23	-25	-27	-22	-25	-35	-46
Net Income / (Loss) Continuing Operations	-16	-20	-20	-19	-23	-25	-27	-22	-25	-35	-46
Total Pre-Tax Income	-16	-20	-20	-19	-23	-25	-27	-22	-25	-35	-46
Total Operating Income	-16	-20	-21	-24	-27	-29	-34	-34	-37	-46	-55
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Operating Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	16	20	21	24	27	29	34	34	37	46	55
Selling, General & Admin Expense	4.24	4.11	9.53	9.82	8.89	8.78	9.97	10	14	15	14
Research & Development Expense	12	16	11	14	18	21	24	24	23	31	41
Amortization Expense	0.03	-	0.03	-	0.00	-	0.03	-	0.02	-	0.02
Total Other Income / (Expense), net	0.45	0.59	1.03	4.52	4.73	4.74	6.75	12	12	11	9.86
Interest & Investment Income	0.45	0.73	1.03	4.55	4.73	4.71	6.75	12	12	11	9.86
Other Income / (Expense), net	0.00	-0.14	0.00	-0.03	0.00	0.03	0.00	-0.02	0.11	0.02	0.00
Basic Earnings per Share	($0.21)	($0.25)	($0.25)	($0.19)	($0.23)	($0.24)	($0.26)	($0.20)	($0.22)	($0.33)	($0.41)
Weighted Average Basic Shares Outstanding	76.51M	76.83M	78.35M	99.01M	99.85M	94.35M	103.46M	110.39M	110.91M	109.04M	112.07M
Diluted Earnings per Share	($0.21)	($0.25)	($0.25)	($0.19)	($0.23)	($0.24)	($0.26)	($0.20)	($0.22)	($0.33)	($0.41)
Weighted Average Diluted Shares Outstanding	76.51M	76.83M	78.35M	99.01M	99.85M	94.35M	103.46M	110.39M	110.91M	109.04M	112.07M
Weighted Average Basic & Diluted Shares Outstanding	76.69M	78.42M	99.58M	100.03M	100.03M	100.49M	110.27M	110.80M	111.44M	112.25M	112.31M

This table details how cash moves in and out of Viking Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	0.01	2.31	5.91	7.40	-16	21	-2.75	11	19	-29
Net Cash From Operating Activities	-8.73	-11	-15	-19	-25	-22	-48	-48	-73	-88
Net Cash From Continuing Operating Activities	-8.73	-11	-15	-19	-25	-22	-48	-48	-73	-88
Net Income / (Loss) Continuing Operations	-23	-15	-21	-22	-26	-39	-55	-69	-86	-110
Consolidated Net Income / (Loss)	-23	-15	-21	-22	-26	-39	-55	-69	-86	-110
Amortization Expense	1.03	2.08	2.94	1.26	1.02	4.19	4.22	1.57	-7.82	-17
Non-Cash Adjustments To Reconcile Net Income	13	0.73	1.11	1.21	5.49	8.40	7.29	9.37	17	31
Changes in Operating Assets and Liabilities, net	0.62	0.85	1.77	0.82	-5.49	5.13	-4.10	9.58	3.23	8.16
Net Cash From Investing Activities	-13	3.03	-1.73	-266	7.46	42	38	55	-179	-553
Net Cash From Continuing Investing Activities	-13	3.03	-1.73	-266	7.46	42	38	55	-179	-553
Purchase of Investments	-16	-17	-23	-348	-362	-281	-168	-121	-478	-1,113
Sale and/or Maturity of Investments	2.56	20	21	82	370	322	206	176	299	560
Net Cash From Financing Activities	22	10	22	300	0.89	0.95	6.88	4.16	271	612
Net Cash From Continuing Financing Activities	22	10	22	292	0.89	0.95	6.88	4.16	271	612
Repurchase of Common Equity	-2.78	-1.10	-0.50	-	-0.07	-0.03	0.00	-6.80	0.00	0.00
Issuance of Common Equity	25	12	23	297	1.11	1.27	7.63	0.85	6.77	11
Other Financing Activities, net	-0.42	-0.03	-0.02	0.13	-0.15	-0.30	-0.75	10	265	602

This table details how cash moves in and out of Viking Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	13	7.08	-18	51	-32	18	140	-152	6.46	-24	11
Net Cash From Operating Activities	-13	-11	-25	-11	-20	-18	-6.13	-29	-22	-31	-52
Net Cash From Continuing Operating Activities	-13	-11	-25	-11	-20	-18	-6.13	-29	-22	-31	-52
Net Income / (Loss) Continuing Operations	-16	-20	-20	-19	-23	-25	-27	-22	-25	-35	-46
Consolidated Net Income / (Loss)	-16	-20	-20	-19	-23	-25	-27	-22	-25	-35	-46
Amortization Expense	0.31	0.03	-0.29	-1.86	-3.07	-2.60	-2.72	-5.34	-4.87	-3.90	-3.00
Non-Cash Adjustments To Reconcile Net Income	2.12	2.28	3.82	4.56	4.74	3.99	8.65	6.93	10	5.03	14
Changes in Operating Assets and Liabilities, net	-0.15	6.37	-8.65	5.09	1.21	5.58	15	-7.86	-2.38	3.10	-18
Net Cash From Investing Activities	27	7.26	2.20	-204	-13	36	-460	-126	26	6.58	63
Net Cash From Continuing Investing Activities	27	7.26	2.20	-204	-13	36	-460	-126	26	6.58	63
Purchase of Investments	-10	-45	-57	-244	-79	-98	-597	-230	-150	-137	-233
Sale and/or Maturity of Investments	37	52	60	39	67	133	137	104	176	144	296
Net Cash From Financing Activities	0.01	11	4.18	267	-0.07	0.19	606	2.91	2.52	1.00	0.35
Net Cash From Continuing Financing Activities	0.01	11	4.18	267	-0.07	0.19	606	2.91	2.52	1.00	0.35
Issuance of Common Equity	-	0.15	-	-	-0.00	0.19	-	-	2.52	1.00	0.35
Other Financing Activities, net	0.01	11	4.18	260	-0.07	-	606	-4.39	-	-	0.00

This table presents Viking Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	15	15	22	302	284	257	211	169	368	908
Total Current Assets	15	14	22	302	284	256	211	167	367	907
Cash & Equivalents	0.77	3.08	8.99	25	8.38	29	26	37	56	27
Short-Term Investments	13	10	12	277	267	219	176	119	307	876
Prepaid Expenses	1.10	0.82	1.28	0.61	7.86	7.72	8.43	12	5.15	1.13
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	0.24	0.56	0.27	0.18	0.76	0.40	0.13	1.49	1.16	1.05
Other Noncurrent Operating Assets	0.24	0.56	0.27	0.18	0.76	0.40	0.13	1.49	1.16	1.05
Total Liabilities & Shareholders' Equity	15	15	22	302	284	257	211	169	368	908
Total Liabilities	6.71	6.49	8.66	4.56	7.14	12	8.78	23	20	28
Total Current Liabilities	1.98	6.48	8.66	4.55	6.78	12	8.78	22	19	27
Accounts Payable	0.59	1.20	1.53	0.96	2.43	3.99	1.44	8.53	7.51	9.81
Accrued Expenses	1.38	1.24	2.26	3.59	4.04	7.81	7.31	13	11	17
Other Current Liabilities	0.00	0.73	1.40	-	0.30	0.33	0.03	0.30	0.32	0.49
Total Noncurrent Liabilities	4.74	0.02	0.00	0.01	0.36	0.06	0.00	1.26	0.94	0.63
Other Noncurrent Operating Liabilities	2.55	-	-	-	0.36	0.03	0.00	1.26	0.94	0.63
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	8.72	8.04	13	298	277	244	202	145	348	880
Total Preferred & Common Equity	8.72	8.04	13	298	277	244	202	145	348	880
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	8.72	8.04	13	298	277	244	202	145	349	881
Common Stock	54	68	94	401	406	413	426	445	734	1,369
Retained Earnings	-46	-60	-81	-103	-129	-168	-223	-292	-378	-488
Treasury Stock	-	-	-	-	-	-	0.00	-6.80	-6.80	0.00

This table presents Viking Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	167	151	401	383	968	947	938	867
Total Current Assets	165	149	399	381	966	946	937	866
Cash & Equivalents	29	18	70	37	196	44	50	38
Short-Term Investments	126	117	323	339	767	898	880	814
Prepaid Expenses	10	3.93	6.45	5.06	0.64	0.14	6.21	14
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	1.54	1.38	1.32	1.36	1.09	1.01	1.16	0.94
Other Noncurrent Operating Assets	1.54	1.38	1.32	1.36	1.09	1.01	1.16	0.94
Total Liabilities & Shareholders' Equity	167	151	401	383	968	947	938	867
Total Liabilities	15	17	15	14	34	26	26	20
Total Current Liabilities	14	16	13	13	33	25	26	20
Accounts Payable	3.14	3.80	5.61	5.71	5.23	11	0.25	7.70
Accrued Expenses	11	12	7.55	7.38	27	14	25	11
Other Current Liabilities	0.30	0.31	0.31	0.32	0.33	0.33	0.48	0.50
Total Noncurrent Liabilities	1.34	1.18	1.10	1.02	0.85	0.77	0.76	0.50
Other Noncurrent Operating Liabilities	1.34	1.18	1.10	1.02	0.85	0.77	0.76	0.50
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	151	134	386	368	934	921	911	847
Total Preferred & Common Equity	151	134	386	368	934	921	911	847
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	151	135	386	368	935	923	910	847
Common Stock	432	453	725	729	1,341	1,351	1,362	1,381
Retained Earnings	-272	-312	-331	-353	-405	-428	-452	-534
Treasury Stock	-6.80	-6.80	-6.80	-6.80	0.00	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from Viking Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-3.38%	49.33%	-50.84%	-44.51%	-34.61%	-11.19%	-45.48%	-33.77%	-57.85%	-54.29%
EBIT Growth	-5.49%	42.37%	-49.33%	-29.02%	-31.89%	-20.49%	-40.73%	-26.44%	-43.23%	-49.57%
NOPAT Growth	48.88%	-15.43%	-37.72%	-37.18%	-24.95%	-30.52%	-30.52%	-26.35%	-43.31%	-49.68%
Net Income Growth	-6.94%	37.05%	-39.68%	-7.22%	-16.84%	-53.21%	-39.23%	-25.24%	-24.73%	-28.02%
EPS Growth	29.64%	75.54%	12.22%	51.90%	5.26%	-50.00%	-31.48%	-26.76%	-1.11%	-10.99%
Operating Cash Flow Growth	-448.66%	-26.80%	-33.30%	-27.08%	-31.98%	12.02%	-118.51%	-1.70%	-51.61%	-19.64%
Free Cash Flow Firm Growth	0.00%	61.23%	-3.57%	-57.90%	-54.74%	13.48%	-75.84%	8.17%	-70.40%	-39.67%
Invested Capital Growth	86.27%	44.13%	-101.75%	-3.63%	139.28%	-372.92%	94.58%	-4,540.64%	-35.45%	-87.90%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-35.32%	14.80%	-3.31%	-18.43%	-4.95%	23.55%	-38.64%	-14.28%	-11.79%	-12.22%
EBIT Q/Q Growth	-33.25%	11.18%	-3.31%	-15.02%	-5.93%	20.38%	-33.12%	-12.43%	-9.60%	-12.68%
NOPAT Q/Q Growth	-55.20%	5.99%	-3.75%	-11.09%	-5.95%	14.87%	-24.86%	-12.42%	-9.80%	-12.65%
Net Income Q/Q Growth	-38.29%	8.94%	-2.19%	-5.52%	-9.38%	-9.72%	-2.63%	-11.68%	-6.24%	-10.90%
EPS Q/Q Growth	-36.80%	40.00%	-6.76%	19.15%	-20.00%	-10.20%	0.00%	-12.50%	1.09%	-9.78%
Operating Cash Flow Q/Q Growth	-48.67%	7.01%	-11.16%	6.33%	-57.78%	22.32%	-16.86%	2.86%	-10.07%	-18.24%
Free Cash Flow Firm Q/Q Growth	0.00%	-1.83%	-15.21%	3.29%	-47.10%	36.20%	-44.05%	8.77%	-11.60%	-13.10%
Invested Capital Q/Q Growth	-49.72%	-16.37%	17.74%	-78.76%	132.34%	-167.51%	92.73%	-171.88%	-72.05%	-35.62%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	50.00%	100.03%	100.09%	100.10%	100.09%
Interest Burden Percent	104.38%	114.01%	106.64%	88.62%	78.52%	199.67%	98.74%	97.74%	85.10%	72.85%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	349.22%	-175.71%	-191.36%	-14.18%	-8.97%	-15.15%	-24.65%	-39.67%	-34.79%	-17.90%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-1,899.52%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	349.22%	-175.71%	-191.36%	-14.18%	-8.97%	-15.15%	-24.65%	-39.67%	-34.82%	-17.92%
Return on Equity Simple (ROE_SIMPLE)	-268.24%	-183.17%	-152.84%	-7.41%	-9.30%	-16.16%	-27.24%	-47.39%	-24.65%	-12.49%
Net Operating Profit after Tax (NOPAT)	-8.40	-9.69	-13	-18	-23	-30	-39	-49	-71	-106
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-225.13%	-46.23%	-53.65%	-2.35%	-1.00%	-3.68%	-7.11%	-10.97%	-5.92%	-0.68%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-33.89%	-20.26%	-12.00%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-22	-13	-19	-25	-33	-40	-56	-70	-101	-151
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-11	-16	-24	-32	-35	-51	-69	-109	-168
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.78	2.98	8.59	1.84	2.09	1.68	1.78	4.96	5.34	5.09
Price to Tangible Book Value (P/TBV)	3.78	2.98	8.59	1.84	2.09	1.68	1.78	4.96	5.34	5.09
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	205.21	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.25	0.41	0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.99	-1.30	-1.25	-1.02	-1.00	-1.00	-1.01	-1.03	-1.05	-1.03
Leverage Ratio	-1.38	1.79	1.70	1.04	1.02	1.04	1.05	1.09	1.09	1.04
Compound Leverage Factor	-1.44	2.04	1.82	0.92	0.80	2.07	1.03	1.07	0.93	0.76
Debt to Total Capital	19.78%	28.90%	20.40%	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	28.90%	20.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	19.78%	0.00%	0.00%	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	80.22%	71.10%	79.60%	100.00%	100.00%	99.99%	100.00%	100.00%	100.11%	100.09%
Debt to EBITDA	-0.10	-0.30	-0.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.56	0.91	1.05	0.00	0.00	7.02	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.26	-0.34	-0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.42	1.02	1.28	0.00	0.00	8.32	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-4.95	-5.90	0.74	72.33	48.88	19.98	23.39	15.87	54.44	95.81
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.08%	-0.10%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.69	2.16	2.52	66.40	41.83	21.12	23.98	7.61	19.19	33.09
Quick Ratio	7.13	2.03	2.38	66.27	40.67	20.48	23.02	7.08	18.92	32.93
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-29	-11	-12	-18	-28	-24	-43	-39	-67	-94
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-32.10	-6.22	-8.97	-45.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-9.77	-6.19	-11.50	-46.42	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-9.77	-6.19	-11.50	-46.42	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.23	-1.80	-3.64	-3.77	1.48	-4.04	-0.22	-10	-14	-26
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	20	1.42	-1.83	-0.13	5.25	-5.52	3.82	-9.94	-3.60	-12
Enterprise Value (EV)	21	14	99	245	304	162	158	565	1,499	3,582
Market Capitalization	33	24	116	547	580	411	360	721	1,862	4,484
Book Value per Share	$0.90	$0.40	$0.47	$4.17	$3.83	$3.35	$2.58	$1.90	$3.49	$7.91
Tangible Book Value per Share	$0.90	$0.40	$0.47	$4.17	$3.83	$3.35	$2.58	$1.90	$3.49	$7.91
Total Capital	11	11	17	298	277	244	202	145	348	880
Total Debt	2.15	3.27	3.45	0.00	0.00	0.03	0.00	0.00	0.00	0.00
Total Long-Term Debt	2.15	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00
Net Debt	-12	-9.88	-17	-302	-276	-248	-202	-155	-362	-903
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.88	-2.38	-3.93	-3.94	1.09	-4.41	-0.35	-10	-14	-23
Debt-free Net Working Capital (DFNWC)	13	11	17	298	277	244	202	145	348	880
Net Working Capital (NWC)	13	7.50	13	298	277	244	202	145	348	880
Net Nonoperating Expense (NNE)	15	5.04	7.23	3.75	2.90	9.63	16	20	15	4.32
Net Nonoperating Obligations (NNO)	-12	-9.85	-17	-302	-276	-248	-202	-155	-362	-906
Total Depreciation and Amortization (D&A)	1.03	2.08	2.94	1.26	1.02	4.19	4.22	1.57	-7.82	-17
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.68)	($0.90)	($0.79)	($0.38)	($0.36)	($0.54)	($0.71)	($0.90)	($0.91)	($1.01)
Adjusted Weighted Average Basic Shares Outstanding	9.68M	23.83M	50.90M	71.99M	72.56M	74.13M	78.36M	76.83M	94.35M	109.04M
Adjusted Diluted Earnings per Share	($3.68)	($0.90)	($0.79)	($0.38)	($0.36)	($0.54)	($0.71)	($0.90)	($0.91)	($1.01)
Adjusted Weighted Average Diluted Shares Outstanding	9.68M	23.83M	50.90M	71.99M	72.56M	74.13M	78.36M	76.83M	94.35M	109.04M
Adjusted Basic & Diluted Earnings per Share	($3.68)	($0.90)	($0.79)	($0.38)	($0.36)	($0.54)	($0.71)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	6.36M	16.28M	25.98M	57.58M	71.96M	72.60M	77.20M	78.42M	100.49M	112.25M
Normalized Net Operating Profit after Tax (NOPAT)	-8.40	-9.69	-13	-18	-23	-30	-39	-49	-71	-106
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-25.09	-7.23	-15.04	-61.62	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-9.40	-5.42	-10.40	-45.33	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-25.09	-7.23	-15.04	-61.62	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-9.40	-5.42	-10.40	-45.33	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-11.89%	-7.44%	-2.43%	0.00%	-0.28%	-0.07%	0.00%	-9.87%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Viking Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-29.87%	-72.88%	-35.73%	-48.99%	-90.98%	-56.17%	-76.66%	-53.76%	-36.20%	-57.33%	-58.91%
EBIT Growth	-22.30%	-61.56%	-27.54%	-34.51%	-68.34%	-43.22%	-65.91%	-43.32%	-33.68%	-58.00%	-62.79%
NOPAT Growth	-20.84%	-62.13%	-26.42%	-34.65%	-68.34%	-44.38%	-65.91%	-43.45%	-34.08%	-57.89%	-62.79%
Net Income Growth	-19.10%	-58.30%	-21.29%	-10.29%	-42.86%	-25.80%	-40.06%	-15.73%	-10.68%	-43.94%	-66.80%
EPS Growth	-23.53%	-66.67%	-19.05%	17.39%	-9.52%	4.00%	-4.00%	-5.26%	4.35%	-37.50%	-57.69%
Operating Cash Flow Growth	-23.55%	11.53%	-134.03%	14.93%	-45.63%	-61.45%	75.11%	-149.35%	-11.72%	-76.76%	-753.13%
Free Cash Flow Firm Growth	-34.70%	66.18%	58.48%	-13.08%	-39.66%	-297.18%	36.53%	56.06%	2.05%	-19.95%	-1,790.52%
Invested Capital Growth	-24.02%	-4,540.64%	-338.38%	-84.57%	-114.04%	-35.45%	-176.77%	-263.13%	-138.37%	-87.90%	84.41%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	7.67%	-28.42%	-2.10%	-23.08%	-18.34%	-5.01%	-15.50%	-7.12%	-4.83%	-21.30%	-16.66%
EBIT Q/Q Growth	8.36%	-26.11%	-0.55%	-15.75%	-14.69%	-7.29%	-16.48%	0.01%	-6.98%	-26.81%	-20.01%
NOPAT Q/Q Growth	8.14%	-25.23%	-1.25%	-15.60%	-14.85%	-7.41%	-16.35%	0.06%	-7.35%	-26.49%	-19.96%
Net Income Q/Q Growth	9.52%	-24.00%	0.14%	1.57%	-17.21%	-9.19%	-11.18%	18.67%	-12.09%	-42.01%	-28.83%
EPS Q/Q Growth	8.70%	-19.05%	0.00%	24.00%	-21.05%	-4.35%	-8.33%	23.08%	-10.00%	-50.00%	-24.24%
Operating Cash Flow Q/Q Growth	-0.42%	19.06%	-125.54%	53.60%	-71.91%	10.27%	65.23%	-364.84%	22.98%	-41.98%	-67.83%
Free Cash Flow Firm Q/Q Growth	11.10%	59.92%	-28.81%	-146.35%	-9.80%	-13.99%	75.63%	-70.55%	-144.75%	-39.59%	-224.45%
Invested Capital Q/Q Growth	-1.38%	-171.88%	-13.40%	40.95%	-17.58%	-72.05%	-94.62%	22.53%	22.82%	-35.62%	80.78%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.17%	99.32%	100.14%	100.00%	100.01%	100.24%	100.10%	100.00%	100.10%	100.12%	100.05%
Interest Burden Percent	97.22%	96.42%	94.97%	80.87%	82.64%	83.91%	80.20%	65.31%	68.36%	76.54%	82.22%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-33.84%	-39.67%	-45.71%	-26.88%	-31.12%	-34.79%	-17.55%	-14.80%	-15.50%	-17.90%	-14.40%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-33.84%	-39.67%	-45.80%	-26.88%	-31.12%	-34.82%	-17.59%	-14.83%	-15.48%	-17.92%	-14.42%
Return on Equity Simple (ROE_SIMPLE)	-40.76%	0.00%	-53.93%	-19.19%	-21.96%	0.00%	-10.04%	-10.50%	-10.88%	0.00%	-15.14%
Net Operating Profit after Tax (NOPAT)	-11	-14	-14	-17	-19	-20	-24	-24	-26	-32	-39
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-2.39%	-3.00%	-3.12%	-0.93%	-1.30%	-1.59%	-0.63%	0.24%	0.10%	-0.48%	-0.75%
Return On Investment Capital (ROIC_SIMPLE)	-	-9.77%	-	-	-	-5.88%	-	-	-	-3.68%	-4.58%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-16	-20	-21	-24	-27	-29	-34	-34	-36	-46	-55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-16	-20	-21	-26	-30	-32	-37	-39	-41	-50	-58
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.38	4.96	9.69	4.18	3.01	5.34	8.77	6.33	7.71	5.09	3.20
Price to Tangible Book Value (P/TBV)	1.38	4.96	9.69	4.18	3.01	5.34	8.77	6.33	7.71	5.09	3.20
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-1.03	-1.04	-1.02	-1.02	-1.05	-1.04	-1.02	-1.02	-1.03	-1.02
Leverage Ratio	1.07	1.09	1.09	1.06	1.06	1.09	1.05	1.03	1.03	1.04	1.03
Compound Leverage Factor	1.04	1.05	1.04	0.85	0.87	0.91	0.84	0.67	0.71	0.80	0.85
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.46%	100.00%	100.00%	100.11%	100.17%	100.25%	99.82%	100.09%	100.03%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.61	16.84	44.27	66.24	45.69	55.08	146.81	136.04	159.54	96.19	81.12
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	-0.20%	0.00%	0.00%	-0.08%	-0.21%	-0.17%	0.13%	-0.10%	-0.10%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.75	7.61	9.55	29.63	28.44	19.19	29.48	37.69	36.47	33.09	44.25
Quick Ratio	11.03	7.08	8.67	29.15	28.07	18.92	29.38	37.55	36.23	32.93	43.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-11	-4.25	-5.48	-14	-15	-17	-3.48	-5.93	-15	-20	-66
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.74	-10	-12	-6.81	-8.00	-14	-32	-25	-19	-26	-4.97
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-0.72	-9.94	-8.90	-3.12	-4.26	-3.60	-20	-18	-11	-12	27
Enterprise Value (EV)	54	565	1,170	1,221	731	1,499	7,239	4,903	6,084	3,582	1,859
Market Capitalization	209	721	1,306	1,614	1,107	1,862	8,202	5,845	7,015	4,484	2,711
Book Value per Share	$1.97	$1.90	$1.72	$3.88	$3.68	$3.49	$9.04	$8.37	$8.21	$7.91	$7.55
Tangible Book Value per Share	$1.97	$1.90	$1.72	$3.88	$3.68	$3.49	$9.04	$8.37	$8.21	$7.91	$7.55
Total Capital	151	145	134	386	368	348	934	921	911	880	847
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-155	-155	-136	-393	-376	-362	-963	-942	-930	-903	-852
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-3.94	-10	-1.85	-7.03	-8.35	-14	-29	-22	-19	-23	-5.41
Debt-free Net Working Capital (DFNWC)	151	145	134	386	368	348	934	921	911	880	846
Net Working Capital (NWC)	151	145	134	386	368	348	934	921	911	880	846
Net Nonoperating Expense (NNE)	4.44	5.36	5.16	2.61	3.45	4.11	3.50	-1.59	-0.65	3.05	6.80
Net Nonoperating Obligations (NNO)	-155	-155	-146	-393	-376	-362	-966	-946	-931	-906	-852
Total Depreciation and Amortization (D&A)	0.31	0.03	-0.29	-1.86	-3.07	-2.60	-2.72	-5.34	-4.87	-3.90	-3.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.21)	($0.25)	($0.25)	($0.19)	($0.23)	($0.24)	($0.26)	($0.20)	($0.22)	($0.33)	($0.41)
Adjusted Weighted Average Basic Shares Outstanding	76.51M	76.83M	78.35M	99.01M	99.85M	94.35M	103.46M	110.39M	110.91M	109.04M	112.07M
Adjusted Diluted Earnings per Share	($0.21)	($0.25)	($0.25)	($0.19)	($0.23)	($0.24)	($0.26)	($0.20)	($0.22)	($0.33)	($0.41)
Adjusted Weighted Average Diluted Shares Outstanding	76.51M	76.83M	78.35M	99.01M	99.85M	94.35M	103.46M	110.39M	110.91M	109.04M	112.07M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	76.69M	78.42M	99.58M	100.03M	100.03M	100.49M	110.27M	110.80M	111.44M	112.25M	112.31M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-14	-14	-17	-19	-20	-24	-24	-26	-32	-39
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-11.02%	-9.87%	-2.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Viking Therapeutics' Financials

When does Viking Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Viking Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Viking Therapeutics' net income changed over the last 9 years?

Viking Therapeutics' net income appears to be on an upward trend, with a most recent value of -$109.96 million in 2024, rising from -$23.40 million in 2015. The previous period was -$85.90 million in 2023. See Viking Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Viking Therapeutics's operating income?

Viking Therapeutics's total operating income in 2024 was -$150.92 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $151.02 million

How has Viking Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Viking Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2024, a change of 0.0%.

How much debt does Viking Therapeutics have?

Viking Therapeutics' total liabilities were at $28.04 million at the end of 2024, a 39.7% increase from 2023, and a 317.7% increase since 2015.

How much cash does Viking Therapeutics have?

In the past 9 years, Viking Therapeutics' cash and equivalents has ranged from $768.55 thousand in 2015 to $55.52 million in 2023, and is currently $26.68 million as of their latest financial filing in 2024.

How has Viking Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Viking Therapeutics' book value per share changed from 0.90 in 2015 to 7.91 in 2024, a change of 777.0%.

Related Companies

This page (NASDAQ:VKTX) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Financials

Frequently Asked Questions About Viking Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Financials

Annual Income Statements for Viking Therapeutics

Quarterly Income Statements for Viking Therapeutics

Annual Cash Flow Statements for Viking Therapeutics

Quarterly Cash Flow Statements for Viking Therapeutics

Annual Balance Sheets for Viking Therapeutics

Quarterly Balance Sheets for Viking Therapeutics

Annual Metrics and Ratios for Viking Therapeutics

Quarterly Metrics and Ratios for Viking Therapeutics

Frequently Asked Questions About Viking Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools